FTSE MIB
34.238,31 -58,00 (-0,17%) Dow Jones
38.386,09 +146,43 (+0,38%) Nasdaq
15.983,08 +55,18 (+0,35%) Nikkei 225
38.405,66 +470,90 (+1,24%) Petrolio
82,92 +0,29 (+0,35%) Bitcoin EUR
58.726,11 -631,68 (-1,06%)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Dopo ore:
| Chiusura precedente | 34,25 |
| Aperto | 34,53 |
| Denaro | 35,32 x 200 |
| Lettera | 35,69 x 100 |
| Min-Max giorno | 34,49 - 36,24 |
| Intervallo di 52 settimane | 3,03 - 49,87 |
| Volume | |
| Media Volume | 372.240 |
| Capitalizzazione | 374,477M |
| Beta (5 anni mensile) | 2,47 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -10,31 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 55,00 |
GlobeNewswireCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
